Altamira Therapeutics Ltd. (CYTOF)
OTCMKTS
· Delayed Price · Currency is USD
0.0651
-0.0100 (-13.27%)
At close: Dec 4, 2025
Altamira Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 0 | 1 | 0.73 | 0.02 | 1.08 | 12.73 | Upgrade
|
| Cash & Short-Term Investments | 0 | 1 | 0.73 | 0.02 | 1.08 | 12.73 | Upgrade
|
| Cash Growth | -94.26% | 36.11% | 4309.00% | -98.46% | -91.52% | 790.04% | Upgrade
|
| Accounts Receivable | - | - | - | 0.01 | 0.02 | - | Upgrade
|
| Other Receivables | 0.21 | 0.35 | 0.09 | 0.82 | 0.73 | 0.07 | Upgrade
|
| Receivables | 0.21 | 0.35 | 0.09 | 0.82 | 0.75 | 0.07 | Upgrade
|
| Inventory | - | - | - | 0.01 | 0.92 | - | Upgrade
|
| Prepaid Expenses | 0.03 | 0 | 0.08 | 0.77 | 0.15 | 0.12 | Upgrade
|
| Other Current Assets | - | 0.19 | 0.55 | 0.29 | 1.59 | 0.21 | Upgrade
|
| Total Current Assets | 0.25 | 1.54 | 1.45 | 1.91 | 4.49 | 13.13 | Upgrade
|
| Property, Plant & Equipment | 0.43 | 0.45 | 0.1 | 0.48 | 0.62 | 0.05 | Upgrade
|
| Long-Term Investments | 1.82 | 2.03 | 2.97 | 0.21 | 0.22 | - | Upgrade
|
| Other Intangible Assets | 4.63 | 4.63 | 4.63 | 4.21 | 15.7 | 10.3 | Upgrade
|
| Total Assets | 7.13 | 8.65 | 9.14 | 6.81 | 21.03 | 23.51 | Upgrade
|
| Accounts Payable | 0.76 | 0.52 | 0.49 | 5.31 | 3.89 | 0.82 | Upgrade
|
| Accrued Expenses | 0.9 | 0.49 | 0.41 | 2.14 | 1.15 | 1.62 | Upgrade
|
| Short-Term Debt | 0.45 | - | - | 6.35 | - | 0.59 | Upgrade
|
| Current Portion of Leases | 0.15 | 0.12 | 0.12 | 0.13 | 0.13 | - | Upgrade
|
| Other Current Liabilities | 0.05 | 0.03 | 0.03 | - | 0.17 | 0.4 | Upgrade
|
| Total Current Liabilities | 2.31 | 1.16 | 1.06 | 13.92 | 5.33 | 3.42 | Upgrade
|
| Long-Term Leases | 0.2 | 0.24 | - | 0.37 | 0.51 | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 1.01 | - | - | Upgrade
|
| Pension & Post-Retirement Benefits | 0.55 | 0.68 | 0.41 | 0.36 | 0.73 | 0.98 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | - | 0.14 | 0.16 | 0.14 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0 | 0.01 | Upgrade
|
| Total Liabilities | 3.06 | 2.09 | 1.47 | 15.8 | 6.73 | 4.55 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0.27 | 0.16 | 0.13 | Upgrade
|
| Additional Paid-In Capital | - | - | 23.89 | 216.92 | 206.79 | 200.32 | Upgrade
|
| Retained Earnings | -4.04 | -3.03 | -21.35 | -226.26 | -192.72 | -181.56 | Upgrade
|
| Comprehensive Income & Other | 8.1 | 9.59 | 5.13 | 0.08 | 0.07 | 0.07 | Upgrade
|
| Shareholders' Equity | 4.07 | 6.57 | 7.68 | -8.99 | 14.3 | 18.95 | Upgrade
|
| Total Liabilities & Equity | 7.13 | 8.65 | 9.14 | 6.81 | 21.03 | 23.51 | Upgrade
|
| Total Debt | 0.79 | 0.36 | 0.12 | 6.84 | 0.63 | 0.59 | Upgrade
|
| Net Cash (Debt) | -0.79 | 0.64 | 0.62 | -6.83 | 0.45 | 12.13 | Upgrade
|
| Net Cash Growth | - | 3.62% | - | - | -96.31% | 748.62% | Upgrade
|
| Net Cash Per Share | -0.18 | 0.23 | 1.25 | -149.93 | 13.53 | 807.00 | Upgrade
|
| Filing Date Shares Outstanding | 5.72 | 4.66 | 2.24 | 0.35 | 0.04 | 0.03 | Upgrade
|
| Total Common Shares Outstanding | 5.72 | 4.66 | 1.48 | 0.06 | 0.04 | 0.03 | Upgrade
|
| Working Capital | -2.06 | 0.38 | 0.4 | -12.01 | -0.84 | 9.71 | Upgrade
|
| Book Value Per Share | 0.71 | 1.41 | 5.19 | -152.33 | 382.25 | 664.06 | Upgrade
|
| Tangible Book Value | -0.55 | 1.94 | 3.05 | -13.2 | -1.4 | 8.65 | Upgrade
|
| Tangible Book Value Per Share | -0.10 | 0.42 | 2.06 | -223.67 | -37.49 | 303.11 | Upgrade
|
| Machinery | - | 0.75 | 0.59 | 0.59 | 0.64 | 0.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.